Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21242854 | 0.81 | NPC1 (0.33) | NPC1RAB9ATP53GLAALDH1A1 | |
| SCHEMBL19112080 | 0.79 | TRPV1 (0.33) | NPC1RAB9ATP53GLAMTNR1A | |
| SCHEMBL27797508 | 0.79 | HSD17B10 (0.36) | NPC1RAB9AMTNR1AMEN1KMT2A | |
| SCHEMBL19380554 | 0.79 | BAZ2B (0.46) | NPC1RAB9AALDH1A1TDP1MTNR1A | |
| SCHEMBL667429 | 0.78 | SMN1; SMN2 (0.37) | NPC1RAB9ATP53GLAALDH1A1 | |
| SCHEMBL9101239 | 0.76 | MTNR1A (0.33) | ALDH1A1MTNR1AMEN1KMT2ACTNNB1 | |
| SCHEMBL19380489 | 0.74 | POLB (0.38) | NPC1RAB9ATP53ALDH1A1TDP1 | |
| SCHEMBL10354177 | 0.74 | MTNR1A (0.32) | NPC1RAB9AALDH1A1TDP1MTNR1A | |
| SCHEMBL1535936 | 0.74 | MTNR1A (0.32) | NPC1RAB9AALDH1A1TDP1MTNR1A | |
| SCHEMBL77894 | 0.74 | KDM4E (0.44) | NPC1RAB9ATP53ALDH1A1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3219204-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3219204-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | INTREXON CORP (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | INTREXON CORP (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3219204-A1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | Intrexon Corporation (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219204-A1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | Intrexon Corporation (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3000317-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-3000317-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| EP-1744619-A4 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1601642-A4 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1744619-A2 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | RheoGene, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1601642-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050266457-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | INTREXON CORPORATION | 2005-12-01 | — | — | US | disclosed |
| WO-2005108617-A2 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | RHEOGENE,INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266457-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | NR2E3, HAVCR2, FCER2 | NPC1 781/4885RAB9A 3944/4885TP53 1858/4885 |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | NR2E3, NR5A1, NR5A2 | NPC1 2399/4885RAB9A 4777/4885TP53 3708/4885 |
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | NR2E3, NR1H4, NR5A2 | NPC1 714/4885RAB9A 4355/4885TP53 838/4885 |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | NPC1 2399/4885RAB9A 4777/4885TP53 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.